Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Crossref DOI link: https://doi.org/10.1007/s13555-021-00490-3
Published Online: 2021-01-29
Published Print: 2021-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Papp, Kim A. http://orcid.org/0000-0001-9557-3642
de Vente, Saskia
Zeng, Jiewei
Flack, Mary
Padilla, Byron
Tyring, Stephen K.
Text and Data Mining valid from 2021-01-29
Version of Record valid from 2021-01-29
Article History
Received: 19 November 2020
Accepted: 18 January 2021
First Online: 29 January 2021